COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
NOVVA Group secures landmark 3.17 GW renewable energy portfolio from ABO Energy to power global AI infrastructure
NOVVA Group acquires 3.17 GW renewable energy portfolio in Argentina from ABO Energy, strengthening global AI infrastructure. Integration of clean power for data centers and infrastructure development -
-
-
COMMUNIQUÉ DE PRESSE
Galaxy Ventures Inc. Announces Major Milestones for Qualifying Transaction: TruSilver Completes $2.5 Million Financing and Appoints Former IAMGOLD Chief Geologist Matt Rees as Director and Vice-President of Exploration
Galaxy Ventures updates on Qualifying Transaction with TruSilver Corp., completion of financing & appointment of Matt Rees as VP of Exploration. TruSilver targeting TSX-V listing -
-
COMMUNIQUÉ DE PRESSE
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs -
COMMUNIQUÉ DE PRESSE
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
NanoViricides, Inc. announces the start of a Phase II Clinical Trial for NV-387 Oral Gummies as a Treatment for Ebola in DRC. NV-387 offers broad-spectrum antiviral properties against Ebola viruses -
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
